Nose-to-Brain Delivery of Chitosan-Grafted Leciplexes for Promoting the Bioavailability and Antidepressant Efficacy of Mirtazapine: In Vitro Assessment and Animal Studies

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Date 2025 Jan 25

PMID 39861109

Authors

Amani M El Sisi

Essam M Eissa

Ahmed H E Hassan

Marina A Bekhet

Fatma I Abo El-Ela

Eun Joo Roh

Rasha M Kharshoum

Adel A Ali

Affiliations

Soon will be listed here.

Abstract

: Mirtazapine (MRZ) is a psychotropic drug prescribed to manage serious sorts of depression. By virtue of its extensive initial-pass metabolic process with poor water solubility, the ultimate bioavailability when taken orally is a mere 50%, necessitating repeated administration. The current inquiry intended to fabricate nose-to-brain chitosan-grafted cationic leciplexes of MRZ (CS-MRZ-LPX) to improve its pharmacokinetic weaknesses and boost the pharmacodynamics aspects. : Primarily, MRZ-loaded leciplexes (MRZ-LPXs) were fabricated and tailored employing a central composite design (CCD). Vesicle diameter size (VS), entrapment efficiency (EE %), cumulative MRZ release percentage (CMRZR %), and total quantity penetrating after twenty-four hours (Q24) were the four parameters assessed. Then, the determined optimum formulation was coated with chitosan (CS-MRZ-LPX) and utilized in pharmacodynamics investigations and in vivo biologic distribution studies in Wistar male rats. : The customized MRZ-LPX formulation had a diameter size of 186.2 ± 3.5 nm and drug EE of 45.86 ± 0.76%. Also, the tailored MRZ-LPX formulation had a cumulative amount of MRZ released of 76.66 ± 3.06% and the total Q24 permeated was 383.23 ± 13.08 µg/cm. Intranasal delivery of the tailored CS-MRZ-LPX revealed notably superior pharmacokinetic attributes inside the brain and circulation compared to the orally administered MRZ suspension and the intranasal free drug suspension ( < 0.05); the relative bioavailability was 370.9% and 385.6% for plasma and brain, respectively. Pharmacodynamics' and immunohistopathological evaluations proved that optimum intranasal CS-MRZ-LPX boosted antidepressant activity compared to the oral and free nasal drug administration. : CS-MRZ-LPX tailored formulation can potentially be regarded as a prospective nano platform to boost bioavailability and enhance pharmacodynamics efficacy. Ultimately, intranasal CS-MRZ-LPX can be considered a promising avenue for MRZ targeted brain delivery as an antidepressant.

References

Natsheh H, Touitou E . Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties. Molecules. 2020; 25(13). PMC: 7412180. DOI: 10.3390/molecules25132959. View

Eid H, Elkomy M, El Menshawe S, Salem H . Development, Optimization, and In Vitro/In Vivo Characterization of Enhanced Lipid Nanoparticles for Ocular Delivery of Ofloxacin: the Influence of Pegylation and Chitosan Coating. AAPS PharmSciTech. 2019; 20(5):183. DOI: 10.1208/s12249-019-1371-6. View

Tong G, Qin N, Sun L . Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J. 2017; 25(6):844-851. PMC: 5605887. DOI: 10.1016/j.jsps.2016.12.003. View

Ranjan O, Shavi G, Nayak U, Arumugam K, Averineni R, Meka S . Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. Arch Pharm Res. 2011; 34(11):1919-29. DOI: 10.1007/s12272-011-1112-1. View

Kaur P, Garg T, Vaidya B, Prakash A, Rath G, Goyal A . Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J Drug Target. 2014; 23(3):275-86. DOI: 10.3109/1061186X.2014.994097. View

Aboud H, Hassan A, Ali A, Abdel-Razik A . Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting. Drug Deliv. 2018; 25(1):1328-1339. PMC: 6058503. DOI: 10.1080/10717544.2018.1477858. View

Abdellatif M, Josef M, El-Nabarawi M, Teaima M . Sertaconazole-Nitrate-Loaded Leciplex for Treating Keratomycosis: Optimization Using D-Optimal Design and In Vitro, Ex Vivo, and In Vivo Studies. Pharmaceutics. 2022; 14(10). PMC: 9611087. DOI: 10.3390/pharmaceutics14102215. View

Chenu F, Guiard B, Bourin M, Gardier A . Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res. 2006; 172(2):256-63. DOI: 10.1016/j.bbr.2006.05.011. View

Serralheiro A, Alves G, Fortuna A, Falcao A . Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci. 2014; 60:32-9. DOI: 10.1016/j.ejps.2014.04.019. View

10.

Ali A, Hassan A, Eissa E, Aboud H . Response Surface Optimization of Ultra-Elastic Nanovesicles Loaded with Deflazacort Tailored for Transdermal Delivery: Accentuated Bioavailability and Anti-Inflammatory Efficacy. Int J Nanomedicine. 2021; 16:591-607. PMC: 7846863. DOI: 10.2147/IJN.S276330. View

11.

Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J . Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Int Immunopharmacol. 2018; 61:385-393. DOI: 10.1016/j.intimp.2018.06.027. View

12.

Salem H, Ali A, Rabea Y, Abo El-Ela F, Khallaf R . Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal. Drug Deliv Transl Res. 2022; 12(12):3083-3103. PMC: 9636110. DOI: 10.1007/s13346-022-01172-z. View

13.

Md S, Khan R, Mustafa G, Chuttani K, Baboota S, Sahni J . Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 2012; 48(3):393-405. DOI: 10.1016/j.ejps.2012.12.007. View

14.

Salazar-Juarez A, Barbosa-Mendez S, Merino-Reyes P, Matus-Ortega M, Hernandez-Calderon J, Anton B . Chronic dosing with mirtazapine does not produce sedation in rats. Braz J Psychiatry. 2017; 39(3):228-236. PMC: 7111384. DOI: 10.1590/1516-4446-2016-2058. View

15.

Panda D, Eid H, Elkomy M, Khames A, Hassan R, Abo El-Ela F . Berberine Encapsulated Lecithin-Chitosan Nanoparticles as Innovative Wound Healing Agent in Type II Diabetes. Pharmaceutics. 2021; 13(8). PMC: 8401853. DOI: 10.3390/pharmaceutics13081197. View

16.

Eissa E, Elkomy M, Eid H, Ali A, Abourehab M, Alsubaiyel A . Intranasal Delivery of Granisetron to the Brain via Nanostructured Cubosomes-Based In Situ Gel for Improved Management of Chemotherapy-Induced Emesis. Pharmaceutics. 2022; 14(7). PMC: 9316995. DOI: 10.3390/pharmaceutics14071374. View

17.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

18.

Vyslouzil J, Dolezel P, Kejdusova M, Kostal V, Benes L, Dvorackova K . Long-term controlled release of PLGA microparticles containing antidepressant mirtazapine. Pharm Dev Technol. 2014; 21(2):214-21. DOI: 10.3109/10837450.2014.991874. View

19.

Abo El-Enin H, Elkomy M, Naguib I, Ahmed M, Alsaidan O, Alsalahat I . Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route. Pharmaceuticals (Basel). 2022; 15(3). PMC: 8955068. DOI: 10.3390/ph15030281. View

20.

Muntimadugu E, Dhommati R, Jain A, Challa V, Shaheen M, Khan W . Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci. 2016; 92:224-34. DOI: 10.1016/j.ejps.2016.05.012. View